Rigel Pharmaceuticals (RIGL) Invested Capital (2010 - 2026)

Rigel Pharmaceuticals has reported Invested Capital for 17 years, with the latest figure at $429.8 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 1187.41% year-over-year to $429.8 million; the trailing twelve-month figure through Mar 2026 stood at $429.8 million (up 1187.41% YoY), and the FY2025 full-year result was $421.3 million, up 3889.51% from the prior year.
• Invested Capital for Q1 2026 stood at $429.8 million, up from $421.3 million in the prior quarter.
• The five-year high for Invested Capital was $429.8 million in Q1 2026, with the low at -$31.8 million in Q3 2023.
• Average Invested Capital over 5 years is $55.8 million, with a median of -$13.6 million recorded in 2022.
• Year-over-year, Invested Capital sank 664.62% in 2023 and jumped 3889.51% in 2025.
• Tracing RIGL's Invested Capital over 5 years: stood at -$13.6 million in 2022, then sank by 57.28% to -$21.4 million in 2023, then soared by 149.31% to $10.6 million in 2024, then jumped by 3889.51% to $421.3 million in 2025, then gained by 2.01% to $429.8 million in 2026.
• The last three Invested Capital figures came in at $429.8 million (Q1 2026), $421.3 million (Q4 2025), and $147.4 million (Q3 2025), per Business Quant data.

Peer Comparison